'Maturity Model' Pilot Might Mean Fewer US FDA Inspections For Medtech
This article was originally published in SRA
Executive Summary
So-called 'mature' medical device companies could put off an inspection by the US Food and Drug Administration for a few years if they independently verify that they have robust metrics in place to gauge manufacturing and product quality, according to a pilot program that the agency hopes to set up by the end of 2017.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.